QV Investors Inc. Sells 68,250 Shares of Solventum Co. (NYSE:SOLV)

QV Investors Inc. cut its stake in shares of Solventum Co. (NYSE:SOLV - Free Report) by 27.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 182,312 shares of the company's stock after selling 68,250 shares during the period. Solventum accounts for about 1.2% of QV Investors Inc.'s investment portfolio, making the stock its 29th biggest holding. QV Investors Inc. owned 0.11% of Solventum worth $12,044,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Copeland Capital Management LLC bought a new stake in Solventum in the 3rd quarter valued at $26,000. Modus Advisors LLC bought a new position in shares of Solventum in the fourth quarter valued at about $25,000. Mather Group LLC. acquired a new stake in shares of Solventum during the 3rd quarter worth about $27,000. Hollencrest Capital Management bought a new stake in shares of Solventum during the 2nd quarter worth about $25,000. Finally, True Wealth Design LLC grew its stake in Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company's stock valued at $33,000 after buying an additional 471 shares during the last quarter.

Solventum Trading Up 2.1 %

Shares of SOLV traded up $1.39 during midday trading on Monday, hitting $68.46. The company's stock had a trading volume of 780,861 shares, compared to its average volume of 1,118,694. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company's fifty day simple moving average is $69.32 and its two-hundred day simple moving average is $65.00.

Analysts Set New Price Targets

SOLV has been the topic of several research reports. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. Stifel Nicolaus started coverage on Solventum in a research report on Tuesday, October 8th. They set a "buy" rating and a $82.00 price objective on the stock. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a "peer perform" rating for the company. Morgan Stanley upped their price target on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Finally, Piper Sandler lifted their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.